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MicroRNA-17-5p Reduces Inflammation and Bone Erosions 
in Mice With Collagen-Induced Arthritis and Directly 
Targets the JAK/STAT Pathway in Rheumatoid Arthritis 
Fibroblast-like Synoviocytes
Aurélie Najm,1  François-Marie Masson,2 Pauline Preuss,3 Steven Georges,2 Benjamin Ory,2 Thibaut Quillard,2 
Shatakshi Sood,4 Carl S. Goodyear,4  Douglas J. Veale,5 Ursula Fearon,6  Benoit Le Goff,3 and 
Frédéric Blanchard2
Objective. To examine microRNA (miRNA) expression across rheumatoid arthritis (RA) phenotypes, along with the 
effects and mechanisms of action of miRNA-17-5p (miR-17).
Methods. A miRNA array was performed in synovial tissue biopsied from patients with treatment-naive erosive RA 
(n = 3) and those with treatment-naive nonerosive RA (n = 3). MicroRNA-17 lipoplex was delivered intraarticularly in 
the murine collagen-induced arthritis model. Clinical, histologic, and structural effects were studied over the course 
of arthritis. In-depth studies of the mechanisms of action of miR-17 were performed in primary RA fibroblast-like 
synoviocytes (FLS) isolated from synovial tissue.
Results. Fifty-five miRNAs including miR-17 were reduced in erosive RA. The miR-17 transfection into arthritic 
paws reduced the clinical inflammation score between day 2 and day 7 (1.9 versus 2.8; P = 0.03). Synovial B cell, 
T cell, macrophage, and polynuclear neutrophil infiltration was significantly reduced. Structural damage was also 
decreased, as shown by a reduction in the number of osteoclasts detected using tartrate-resistant acid phosphatase 
staining (osteoclast surface/bone surface 18% versus 32%; P = 0.005) and erosion score by computed tomography 
analysis (1.7 versus 2.9; P = 0.023). Proinflammatory cytokines from the interleukin-6 (IL-6) family and IL-1β 
expression were also significantly reduced, but tumor necrosis factor was not. MicroRNA-17 directly targeted the 
3′-untranslated regions of STAT3 and JAK1. STAT3 and JAK1 messenger RNA (mRNA) and protein expression were 
reduced in RA FLS following miR-17 transfection. STAT3 and JAK1 mRNA and activation of STAT3, as assessed by 
immunohistochemistry, were also reduced in injected paws (% stained area 0.62% versus 0.93%; P = 0.035).
Conclusion. We demonstrate an antiinflammatory and antierosive role of miR-17 in vivo. This effect involves the 
suppression of the IL-6 family autocrine-amplifying loop through the direct targeting of JAK1 and STAT3.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inflammatory disease of 
the joints, affecting 0.5–1% of the population worldwide (1). Inflam-
matory cytokines including tumor necrosis factor (TNF), interleu-
kin-1 (IL-1), IL-17, and IL-6 are part of the inflammatory milieu 
in RA (2). Most notably, they are potent stimulators of synovial 
fibroblasts, cells that are important contributors to and regulators 
of inflammation through their production of inflammatory cytokines 
such as IL-6 family cytokines (IL-6, leukemia inhibitory factor [LIF]) 
and chemokines (3). Synergistic effects and autocrine amplifi-
cation loops involving the IL-6/JAK/STAT pathway have been 
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observed with these cytokines in fibroblasts, resulting in chronic 
inflammation (3,4). Although biologic drugs (e.g., anti-TNF, anti–
IL-6 receptor [IL-6R], anti–IL-17) and small molecules (JAK inhib-
itors) have transformed patient care, reducing both inflammation 
and joint destruction, 30% of patients switch or discontinue their 
biologics in the first year of treatment due to nonresponse (5). 
These data highlight the need for innovative therapies, especially 
for patients with aggressive and erosive RA (6).
A field of research currently in full expansion is the study 
of microRNA (miRNA or miR) in chronic inflammatory rheumatic 
diseases, particularly RA (7). Alterations in miRNA expression are 
involved not only in tumor development but in inflammatory pro-
cesses such as rheumatic diseases. The miR-17–92 cluster has 
been the subject of intense research in recent years due to its key role 
in cancer development and progression. The MIR17HG gene (miR-
17–92 cluster host gene [non–protein coding] located on chromo-
some 13 [13q31.3]) encodes a polycistronic primary transcript that 
yields ≥6 mature miRNAs: miR-17, miR-18a, miR-19a, miR-19b, 
miR-20, and miR-92 (8). Beyond its involvement in oncology (9), 
this cluster has more recently been studied in rheumatic diseases. 
Expression of miR-17-5p is reduced in synovial fibroblasts, periph-
eral blood mononuclear cell (PBMCs), and synovial tissue from RA 
patients, suggesting a crucial role in RA pathogenesis (10). In vitro, 
the transfection of pre–miR-17 into RA fibroblast-like synoviocytes 
(FLS) has an antiinflammatory effect through direct targeting of the 
MAP3K5 kinase (apoptosis signal–regulating kinase 1 [ASK1]) in the 
TNF signaling pathway, thus reducing IL-6 production (10).
To date, however, the mechanisms involved in regulating the 
antiinflammatory effect of miR-17 remain unclear. Moreover, no 
studies have investigated the therapeutic potential and mech-
anism of action of the miR-17–92 cluster in murine models of 
arthritis. We undertook this study to assess the expression of 
the miR-17–92 cluster in different RA phenotypes (erosive and 
nonerosive), to further elucidate the mechanisms and direct tar-
gets involved in the antiinflammatory role of miR-17-5p, and to 
investigate the therapeutic effects of miR-17-5p in arthritis.
MATERIALS AND METHODS
Patient recruitment, synovial membrane miRNA array, and RNA 
sequencing of arthritic paws are described in detail in Supplemen-
tary Methods (available on the Arthritis & Rheumatology website at 
http://onlin elibr ary.wiley.com/doi/10.1002/art.41441/ abstract).
The RNA sequencing data discussed here have been depos-
ited in NCBI’s Gene Expression Omnibus and are accessible 
through GEO Series accession no. GSE139269 (https://www.ncbi. 
nlm.nih.gov/geo/query/ acc.cgi?acc=GSE13 9269).
Reverse transcription–quantitative polymerase chain 
reaction (RT-qPCR) analysis. Human and mouse tissues were 
homogenized using a DI25 Ultra-Turrax homogenizer (IKA) in 
QIAzol lysis reagent (Qiagen). Cell cultures were lysed by scraping 
in QIAzol. Total RNA, including miRNA, was isolated using a mi -
RNeasy Kit (Qiagen). For messenger RNA (mRNA) and miRNA, 
RT-qPCR was carried out as previously described (11,12). Anal-
ysis was performed using hypoxanthine guanine phosphoribosyl-
transferase (for mRNA) or RNU6B (for miRNA) as invariant control, 
and results were expressed as 2–ΔCt.
Collagen-induced arthritis (CIA) mouse model. Animal 
experimentation was performed according to institutional guidelines 
and was approved by the French ethical committee CEEA.PdL.06 
and by local veterinary services. Eight-week-old male DBA/1 mice 
were immunized as previously described (11). Lipoplexes of miR-
17-5p mimic or irrelevant miRNA control (mirVana; Thermo Fisher 
Scientific) were prepared using Lipofectamine (RNAiMAX Trans-
fection Reagent) according to the instructions of the manufacturer 
(Thermo Fisher Scientific). Intraarticular injections of miRNA lipoplex 
(8 × 10−12 moles of miRNA per injection) were administered into 
arthritic ankles with 30-gauge needles at the first signs of inflammation 
(day 1) and then every 48 hours. In each animal, only hind paws were 
considered for injection, and ankles were considered independently. 
Animals with arthritis were randomized into different groups (nonin-
jected mice with arthritis, miRNA control–injected mice with arthritis, 
anti-miRNA control–injected mice with arthritis, miR-17–injected mice 
with arthritis, and anti–miR-17–injected mice with arthritis). The anti–
miR-17 and miR-17 experiments were conducted as independent 
experiments.
The injection protocol was defined through prior experiments 
in order to select the best concentration, volume, and frequency 
of injections. Inflammatory symptoms were assessed daily by clin-
ical scoring, and mice were euthanized on day 4 or day 7 (peak 
phase). Structural damage (chondrolysis, bone erosions) was 
analyzed with a high-resolution SkyScan 1076 micro–computed 
tomography (micro-CT) system (11). Semiquantitative scores 
(0–4) were obtained for chondrolysis and bone erosions after 
3-dimensional reconstruction. Ankles were then fixed, decalcified, 
and embedded. All histologic staining was performed as previ-
ously described (11). For clinical, histologic, and micro-CT analy-
sis, researchers were blinded with regard to treatment group.
Cell culture. Primary RA FLS were isolated from syn-
ovial membranes obtained from consenting RA patients 
undergoing arthroplasty (11). Primary RA macrophages were 
generated from RA synovial fluid monocytes using granulocyte– 
macrophage colony-stimulating factor/interferon-γ (IFNγ), as 
previously described (13). THP-1 monocytic cells (American Type 
Culture Collection) were stimulated with phorbol 12-myristate 
13-acetate (Sigma) to induce differentiation into active mac-
rophage-like cells, as described (11). MicroRNA-17-5p mimic 
or irrelevant miRNA control was transfected for 24 hours at a 
final concentration of 6 nM using Lipofectamine, according to 
the instructions of the manufacturer. Cells were stimulated with 
IL-1β (1 ng/ml; R&D systems), TNF (10 ng/ml; R&D systems), or 
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lipopolysaccharide (LPS) (10 or 100 ng/ml; Sigma) for 24 hours 
and then lysed in radioimmunoprecipitation assay buffer. Pri-
mary antibodies (all from Cell Signaling Technology) were used 
to detect proteins of interest by Western blotting, as previously 
described (11). Enzyme-linked immunosorbent assay for the 
detection of IL-6 in culture supernatants was performed accord-
ing to the instructions of the manufacturer (R&D Systems).
Luciferase reporter assays. Luciferase assays were per-
formed as previously described (14,15) and are described in Sup-
plementary Methods (http://onlin elibr ary.wiley.com/doi/10.1002/
art.41441/ abstract).
Statistical analysis. To assess the significance of dif-
ferences between groups, Mann-Whitney U tests or paired 
 Wilcoxon-Mann-Whitney tests were performed using  GraphPad 
Prism, version 6. P values less than 0.05 were considered 
 significant. Data are presented as the mean ± SEM, and 95% 
confidence intervals (95% CIs) were calculated.
RESULTS
Differential expression of miRNAs depending on 
RA phenotype. We assessed the expression of 754 known 
miRNAs by performing low-density TaqMan arrays in knee synovial 
Figure 1. Expression of the microRNA-17–92 (miR-17–92) cluster is decreased in erosive rheumatoid arthritis (RA). A, Volcano plot showing 
differential expression of 754 miRNAs in erosive RA synovium (n = 3) and nonerosive RA synovium (n = 3), as assessed by TaqMan array. 
Up-regulated miRNAs (>2-fold change) in erosive RA are shown in green, down-regulated miRNAs in red. Three miRNAs from the miR-17–92 
cluster were significantly down-regulated in erosive RA (P < 0.05). B, Hierarchical clustering of ΔCt values of the top 51 differentially expressed 
miRNAs (>2-fold change; P < 0.05) in erosive and nonerosive RA synovium. The 3 miRNAs from the miR-17–92 cluster are shown with red 
borders. C, Target genes and pathways of miR-17, miR-18a, and miR-20a as analyzed with DIANA-mirPath version 3 software. D, Down-
regulated expression of the miR-17–92 cluster in RA synovium (n = 3) compared to osteoarthritis (OA) synovium (n = 4), as assessed by reverse 
transcription–quantitative polymerase chain reaction. Symbols represent individual subjects; bars show the mean ± SEM. * = P < 0.05 by Mann-
Whitney U test. TGF = transforming growth factor.
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samples from patients with erosive RA (n = 3) (≥1 erosion visible 
on plain hand and feet radiographs) and from patients with noner-
osive RA (n = 3). All patients had early RA, were naive to treatment 
with disease-modifying antirheumatic and biologic drugs, and 
were seropositive for both rheumatoid factor and anti–citrullinated 
protein antibody (Supplementary Table 1A, http://onlin elibr ary.
wiley.com/doi/10.1002/art.41441/ abstract). The median disease 
duration was 2.3 months.
Fifty-five miRNAs were significantly down-regulated in 
 erosive RA and only 2 miRNAs were up-regulated (>2-fold 
change)  (Figures 1A and B). These dysregulated miRNAs are 
known to target numerous genes implicated in various path-
ways apparently  unrelated to bone erosion, such as thyroid 
hormones or proteoglycans in cancer (Supplementary Table 2, 
http://onlin elibr ary.wiley.com/doi/10.1002/art.41441/ abstract). 
Interestingly, 3 miRNAs from the miR-17–92 cluster were sig-
nificantly down-regulated in erosive RA: miR-17-5p (2.15-fold 
change [95% CI 1.3–3.5]), miR-18a-3p (2.2-fold change [95% 
CI 1.3–3.56]), and miR-20a-5p (2.4-fold change [95% CI 1.3–
4.2]). These 3 miRNAs are known to target genes implicated 
in transforming growth factor β (SMAD4, SMAD5, SMAD6, 
TGFBR2) or MAPK (MAP3K1, MAP3K5) signaling pathways or 
in hepatitis B (JAK1, STAT3) (Figure 1C), i.e., genes that have 
previously been described in inflammatory or bone remodeling 
processes.
In order to assess the expression of miRNAs from clus-
ter 17–92 across disease states, RT-qPCR was performed in 
synovial tissue from a different cohort of patients with either 
nonerosive osteoarthritis (OA) (n = 4) or established erosive RA 
(n = 3) (mean disease duration 6 years) (Supplementary Table 1B, 
http://onlin elibr ary.wiley.com/doi/10.1002/art.41441/ abstract). 
Once again, miR-17-5p, miR-18a-5p, and miR-20a-5p, as well 
as miR-92a-5p, were down-regulated in erosive RA synovium 
compared to OA synovium (Figure 1D). Interestingly, findings 
from prior studies in RA FLS (10) have suggested an antiinflam-
matory role of miR-17-5p (hereafter referred to as miR-17), and 
we sought to study examine the role and mechanisms of action 
of miR-17 in more detail.
Antiinflammatory role of miR-17 in the CIA mouse 
model. Arthritic paws (score ≥1) of mice with CIA were injected 
intraarticularly with either irrelevant miRNA (miRNA  control) 
or miR-17 lipoplex every other day. At the peak of inflammation 
(day 7, after 3 miRNA injections), paws injected with  miR-17 
lipoplex displayed an increase of miR-17 expression compared to 
control-injected paws (Figure 2A), whereas endogenous miR-17 
expression was significantly reduced in arthritic ankles compared 
to nonarthritic ankles. The injection of miR-17 significantly reduced 
inflammation scores beginning on day 2, compared to the miRNA 
control group, and this effect persisted through day 7 (Figure 2B). 
There was no significant difference in arthritis scores between the 
group injected with miRNA control and the noninjected group.
Injection of miR-17 also significantly reduced the synovial 
inflammation score (obtained by hematoxylin and eosin staining) 
and specific synovial cell infiltration including CD45R+ B cells, 
CD3+ T cells, Iba1+ macrophages, and Ly6G+ polynuclear neu-
trophils (Figures 2C and D). No increase of cell apoptosis was 
observed in the miR-17–injected group (Supplementary Figure 1A, 
http://onlin elibr ary.wiley.com/doi/10.1002/art.41441/ abstract). 
Injection of miR-17 significantly reduced the joint erosion score 
(assessed by micro-CT), cartilage degradation, and osteoclast 
surface/bone surface percentage (assessed by tartrate-resistant 
acid phosphatase staining) (Figures 2C and E). We also performed 
injections of miR-17 lipoplex in mice with CIA that were eutha-
nized at the resolution phase of arthritis (day 14) instead of during 
the peak phase. We observed a significant reduction in clinical 
scores, mostly at the peak phase of inflammation (days 2–10) 
(Supplementary Figure 1B). Notably, when mice were injected 
with anti–miR-17 in order to neutralize the endogenous miR-17 in 
arthritic paws, we observed a significant increase in clinical arthri-
tis scores from day 3 to day 11 (Supplementary Figure 1C).
MicroRNA-17 acts by targeting the IL-6 pathway. In 
order to gain insight into the mechanism of action of miR-17, we 
assessed gene expression through RNA sequencing in miR-17–
injected paws at the peak of inflammation (Figures 3A and B). We 
found 1,289 genes that were differentially expressed in miR-17–
injected paws: 546 up-regulated genes and 743 down- regulated 
genes. Interestingly, enrichment of IFN-responsive genes was 
observed for genes up-regulated by miR-17 (Ifit3, Ifit3b, Irf7, 
Stat1), as well as genes implicated in antigen processing (B2m, 
H2-K1) or in ossification (Col2a1, Mgp) (Figures 3B–D and Sup-
plementary Table 3, http://onlin elibr ary.wiley.com/doi/10.1002/
art.41441/ abstract). Moreover, enrichment of genes related to 
inflammatory response (Cd14, Nlrp3), osteoclast differentiation 
(Trap, Nfatc1, and the matrix-remodeling enzymes Ctsk and 
MMP9), neutrophil chemotaxis (Cxcl1, Cxcr2), or cytokine-receptor 
interaction was observed among down-regulated genes. Of 
interest, several genes from the IL-6 family and/or STAT3 target 
genes were down-regulated by miR-17 (Il6, Lif, Osm, Ccl2, Ccl20, 
Socs3) (Figures 3B, C, and E and Supplementary Tables 3 and 
4, http://onlin elibr ary.wiley.com/doi/10.1002/art.41441/ abstract).
We next confirmed by RT-qPCR that the expression of 
mRNA for genes encoding IL-6 family cytokines and/or STAT3 
target genes (Il6, Osm, Rankl) was significantly reduced in ankles 
injected with miR-17 lipoplex (Figure 3E). IL-1β transcripts were 
also significantly reduced, but TNF was not (Figure 3F).
Reduction of IL-6 (but not of macrophage)  secretion 
in RA FLS by miR-17. It appears that miR-17 is prominently 
expressed in endothelial cells. Its expression in fibroblasts 
appears to be variable, while lower expression levels were 
observed in neutrophils, T cells, and B cells (Supplementary 
Figure 2, http://onlin elibr ary.wiley.com/doi/10.1002/art.41441/ 
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abstract). More over, miR-17 was previously shown to repress 
IL-6 production in RA FLS in culture. RA FLS were efficiently 
transfected with miRNA lipoplex (>95% of transfected cells) and 
transfection of miR-17 led to 100–1,000-fold increased expres-
sion of miR-17 (Supplementary Figures 3A and B, http://onlin e 
libr ary.wiley.com/doi/10.1002/art.41441/ abstract). Overexpres-
sion of miR-17 did not alter RA FLS survival or proliferation (Sup-
plementary Figure 3C). After 24 hours of stimulation with IL-1β, 
TNF, or LPS, we confirmed that overexpression of miR-17 signif-
icantly reduced IL-6 secretion in RA FLS from 4 different patients 
(Figure 4A). However, transfection of anti–miR-17 showed over-
all no effect on IL-6 secretion (data not shown). A low level of 
endogenous miR-17 expression in RA FLS may have precluded 
its efficient neutralization with anti– miR-17 (10).
In order to determine whether miR-17 could have an effect in 
other immune cells, we studied the effect of miR-17 transfection 
in RA macrophages generated from RA synovial fluid monocytes. 
Although RA or THP-1 macrophages were efficiently transfected 
by miRNA lipoplex (>90% of transfected cells) and by miR-146 
(used as positive control) (14), the LPS-induced secretion of IL-6 
was not affected by miR-17 transfection (Figure 4B), in contrast to 
the findings in RA FLS (Figure 4A).
Reduced PBMC migration and osteoclastogenesis 
in miR-17–transfected RA FLS. We studied the role of miR-
17 in RA FLS on immune cell migration and osteoclastogenesis. 
PBMC migration was reduced significantly in wells containing miR-
17–transfected RA FLS (Figure 4C). After 14 days, the number of 
Figure 2. Effect of microRNA-17 mimic lipoplex (miR-17) injection into the ankles of mice with collagen-induced arthritis (CIA). A, On day 7, 
miR-17 was overexpressed in the ankles of mice with CIA that were injected with the miR-17 lipoplex. B, A significant reduction in clinical arthritis 
scores in miR-17–injected ankles is shown. C, On day 7, miR-17 significantly reduced synovial inflammatory infiltrate and joint erosion, as shown 
by inflammation scores obtained using hematoxylin and eosin (H&E) staining, as well as Ly6G and Iba1 staining scores. Synovial CD45R+ and 
CD3+ positive cells are shown. Osteoclast surface/bone surface (OcS/BS) percentage was determined with tartrate-resistant acid phosphatase 
(TRAP) staining, using NDPview2 software. Chondrolysis was evaluated based on Safranin O staining scores. Joint erosions were analyzed by 
micro–computed tomography (micro-CT) using Skyscan CtVol software. Scores for the talocrural joint from the micro-CT analysis were used. 
Symbols represent individual ankles; bars show the mean ± SEM. * = P < 0.05; ** = P < 0.005, by Mann-Whitney U test. D, Representative 
immunohistochemistry images of CD3+ T lymphocytes are shown. E, Representative micro-CT images of joint erosions are shown. No damage 
from the injection was observed clinically, histologically, or structurally. NA = nonarthritic, noninjected ankles (n = 3); NI = arthritic noninjected ankles 
(n = 3); miR-CT = arthritic ankles injected with irrelevant miRNA lipoplex control (n = 6 or n = 7); miR-17 = arthritic ankles injected with miR-17 
(n = 6). Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.41441/abstract.
ANTIINFLAMMATORY ROLE OF miR-17 IN RA |      2035
osteoclasts was significantly reduced in wells supplemented with 
conditioned media from RA FLS transfected with miR-17 com-
pared to miRNA controls (Figure 4D). These findings suggest that 
transfection with miR-17 in RA FLS could be responsible for the 
inhibition of immune cell migration in the synovial tissue, along with 
reduction in erosions, via suppression of osteoclastogenesis.
JAK1/STAT3 pathway directly targeted by miR-17. In 
order to gain further insight into the miR-17 mechanism of action, 
we analyzed the expression of genes that could be implicated in 
IL-6 production in RA FLS that were stimulated with TNF. IL-6 and 
LIF transcripts were significantly reduced in miR-17–transfected 
RA FLS (Figure 5A). The other IL-6 family members, oncostatin M 
(OSM) and IL-11 or the osteoclastogenic cytokine RANKL, which 
were also found to be down-regulated by miR-17 in arthritic paws, 
were not detected in RA FLS. No difference in expression of the 
receptor chain’s LIF receptor (LIFR), OSM receptor, or gp130 
was observed. To further depict miR-17 direct targets, we per-
formed in silico analyses (TargetScan and DianaLab). Most of the 
genes described as potential miR-17 targets belonged to the TNF 
and IL-6 family signaling pathways such as ASK1, TRAF2 (10), 
JAK1 (15), STAT3 (16), or several SMAD pathways (17), among 
Figure 3. MicroRNA-17 suppresses expression of interleukin-6 (IL-6) family cytokines and STAT3 target genes in the ankles of mice with 
CIA. A, Volcano plot showing differential expression of genes in the ankles of mice with CIA, as assessed by RNA sequencing on day 7 after 
miR-17 lipoplex injection. The top 8 up-regulated genes (>2-fold change; adjusted P < 0.01) in ankles injected with the miR-17 mimic lipoplex (n 
= 4) compared to ankles injected with irrelevant miRNA control (n = 3) and the top 10 down-regulated genes are shown. Differential expression 
analysis was performed with DESeq2. B, Heatmap representation of the top 40 differentially expressed genes (adjusted P < 0.01). C, Enriched 
biologic processes and pathways, determined using DAVID ontology software on all up-regulated and down-regulated genes (adjusted 
P < 0.01). D and E, Gene Set Enrichment Analysis performed on all differentially expressed genes (1,289 genes; adjusted P < 0.01). Enrichment 
of interferon-responsive genes for genes up-regulated by miR-17 (D) and enrichment of genes related to IL-6 deprivation for those down-
regulated by miR-17 (E) are highlighted. F, Confirmation of down-regulated expression of genes encoding IL-6 family cytokines and/or STAT3 
target genes in ankles injected with miR-17 lipoplex (n = 6 per group), as assessed by reverse transcription–quantitative polymerase chain 
reaction. Symbols represent individual ankles; bars show the mean ± SEM. * = P < 0.05; ** = P < 0.005, by Mann-Whitney U test. TNF = tumor 
necrosis factor; NES = normalized enrichment score; FDR = false discovery rate (see Figure 2 for other definitions). Color figure can be viewed 
in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.41441/abstract.
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others. JAK1 and STAT3 transcripts were significantly reduced in 
cells transfected with miR-17 (Figure 5A). Other JAK and STAT 
transcripts were not down-regulated by miR-17. Interestingly, we 
confirmed the reduction in JAK1 and STAT3 expression at the 
protein level after miR-17 transfection. Expression of other JAK 
and STAT proteins was unaltered (Figure 5B). Expression of miR-
17 did not alter the expression of genes implicated in the TNF 
signaling pathway (TRAF2, TRAF6, NFkB, ASK1) or of Smad fam-
ily members (Figure 5B and Supplementary Figure 4, http://onlin 
elibr ary.wiley.com/doi/10.1002/art.41441/ abstract ).
In order to confirm that miR-17 directly targeted JAK1 and 
STAT3 mRNA, we performed 3ʹ-untranslated region (3ʹ-UTR) assays in 
HEK 293T cells. The results confirmed that miR-17 was able to signif-
icantly reduce JAK1 and STAT3 3ʹ-UTR luciferase activity (Figure 5C).
The above findings suggested that miR-17 directly targets 
the JAK1/STAT3 pathway rather than the TNF signaling pathway. 
To confirm this hypothesis, we next used promoter-luciferase 
reporter plasmids driven by NF-κB or STAT3. Interestingly, we 
observed a significant decrease in STAT3 activity after miR-17 
transfection, but no effect on NF-κB activity was seen (Figure 5D).
TNF activates an autocrine loop involving IL-6 
family members. To further elucidate the miR-17 mechanism 
of action, we compared the effects of several JAK/STAT signaling 
pathway inhibitors to the effects of miR-17. First, TNF increased 
STAT3 activation/phosphorylation (Tyr705/phospho-STAT3), and the 
JAK1 inhibitor ruxolitinib totally abolished STAT3 activation in RA 
FLS (Figure 5E). As observed with miR-17, the JAK1 inhibitor also 
reduced IL-6 secretion induced by TNF (Figure 5F). Similar effects 
were observed with neutralizing antibodies against gp130, the com-
mon receptor chain used by all IL-6 family cytokines, or against the 
cytokine LIF. In contrast, IL-6R or OSM neutralization did not alter 
IL-6 secretion (Figure 5F), in accordance with their absence in RA 
FLS (Figure 5A). Therefore, TNF appeared to induce IL-6 secretion 
partly through activation of an autocrine-amplifying loop involving 
LIF, gp130, JAK1, and STAT3. When ruxolitinib and miR-17 lipoplex 
were combined, there was no additional antiinflammatory effect, 
compared to the effect of a single treatment (Figure 5G). These 
results suggest that both share the same targets, JAK1 and STAT3.
Suppression of the JAK1/STAT3 pathway by miR-17 in 
ankles of mice with CIA. Finally, we examined whether miR-17 
lipoplex exerted its effect on arthritic paws through the same mech-
anism as in RA FLS (via JAK1 and STAT3 targeting). We assessed 
expression levels at an early time point (day 4) and observed a 
significant reduction in JAK1 and STAT3 transcripts (Figure 6A). 
Tyk2 expression was also significantly reduced, but STAT4 was 
not (Figure 6A). In addition, we confirmed the reduction of STAT3 
activation by performing phospho-STAT3 immunohistochemistry 
in ankle tissue (Figure 6B).
DISCUSSION
In this report, we have presented evidence of an antiin-
flammatory role of miR-17. Among a panel of identified miRNAs 
Figure 4. MicroRNA-17 suppresses interleukin-6 (IL-6) secretion in 
rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS). A, RA FLS 
from 4 patients were transfected with the microRNA-17-5p mimic 
(miR-17) or the irrelevant microRNA (miRNA) control (miR-CT) and 
then stimulated for 24 hours with IL-1β, tumor necrosis factor (TNF), or 
lipopolysaccharide (LPS). Secretion of IL-6 in the culture supernatants is 
shown. B, RA macrophages (Macro) were generated from RA synovial 
fluid monocytes, transfected with the indicated miRNA, and stimulated 
with LPS. THP-1 monocytic cells were differentiated, transfected with 
the indicated miRNA, and stimulated with LPS. Secretion of IL-6 in the 
culture supernatants was assessed by enzyme-linked immunosorbent 
assay. C, Peripheral blood mononuclear cells were collected and 
counted after 4 hours of migration through a 5.0-μm Transwell system 
with control- or miR-17–transfected RA FLS from 3 patients. D, CD14+ 
cells from healthy donors were differentiated into osteoclasts (OCs) and 
exposed to conditioned medium (1:4 dilution) from control- or miR-17–
transfected RA FLS (stimulated for 48 hours) from 3 different patients. 
The number of tartrate-resistant acid phosphatase (TRAP)–positive 
multinucleated osteoclasts is shown. In A (right panel) and B, results are 
shown as the mean ± SEM. a = P < 0.05 by paired Wilcoxon-Mann-
Whitney test; * = P < 0.05 versus control by Mann-Whitney U test. E, 
TRAP staining is shown. Original magnification × 20. 146 = miR-146a-
5p (positive control); NT = not transfected. Color figure can be viewed 
in the online issue, which is available at http://onlinelibrary.wiley.com/
doi/10.1002/art.41441/abstract.
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associated with the erosive phenotype of RA, we chose to 
study, in depth, the effects of miR-17 and its mechanism of action. It 
has previously been shown that MiR-17 exerts an antiinflammatory 
effect in RA FLS (10). Here, we further elucidated the mechanisms 
involved in mediating the antiinflammatory effects of miR-17 both in 
RA FLS and in the CIA murine model. The transfection of miR-17 
into mouse ankles significantly reduced secretion of proinflamma-
tory cytokines (IL-6, IL-1β) as well as inflammatory cell infiltration. Of 
interest, both innate immune cells (macrophages and osteoclasts) 
and adaptive immune cells (B and T lymphocytes) known to be 
involved in RA pathophysiology were significantly reduced in the 
synovial tissue, suggesting a wide-ranging role of miR-17. Despite 
the variability of arthritis disease course across experiments, previ-
ously described in the CIA model (18), the antiinflammatory effect 
of miR-17 has consistently been demonstrated here.
The effect exerted by miR-17 in reducing IL-6 expres-
sion directly involved the JAK1/STAT3 pathway, and our data 
suggest that the suppression of the JAK1/STAT3 axis was the 
Figure 5. MicroRNA-17 targets JAK1 and STAT3. A, RA FLS from 4 patients were transfected with miR-CT or miR-17, stimulated with TNF, 
and analyzed for expression of the indicated genes by reverse transcription–quantitative polymerase chain reaction. B, RA FLS from 3 patients 
were transfected with miR-CT or miR-17, stimulated with TNF, and analyzed for expression of the indicated proteins by Western blotting. 
Actin was used as an internal control. Representative images from 1 patient (left) and quantification of the protein expression levels from the 3 
patients (right) are shown. C, HEK 293T cells were transfected with luciferase reporter plasmids containing the indicated 3ʹ-untranslated region 
(3ʹ-UTR) together with miR-17 or miR-CT. Luciferase activity was measured 24 hours after transfection. D, HEK 293T cells were transfected 
with promoter-luciferase reporter plasmids driven by NF-κB or STAT3, together with miR-17 or miR-CT, and stimulated with TNF or oncostatin 
M (OSM) for the indicated amount of time. E, RA FLS were stimulated for 24 hours with TNF and the JAK1 inhibitor ruxolitinib, as indicated. 
Phosphorylation of STAT3 (Tyr705) was analyzed by Western blotting. F, RA FLS were stimulated for 24 hours with TNF-neutralizing antibodies 
and ruxolitinib, as indicated. Secretion of IL-6 in the culture supernatants was assessed by enzyme-linked immunosorbent assay (ELISA). G, 
RA FLS were transfected with miR-17 or miR-CT and then stimulated for 24 hours with TNF and ruxolitinib, as indicated. Secretion of IL-6 in the 
culture supernatants was assessed by ELISA. In C–G, One representative experiment of ≥3 independent experiments is shown. Bars show the 
mean ± SEM. * P < 0.05 by Mann-Whitney U test. ND = not detected; LIFR = leukemia inhibitory factor receptor; CT = control without antibody; 
IgG = control with irrelevant antibody (see Figure 4 for other definitions).
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primary mechanism of action (Figure 6C). In contrast to previ-
ous findings, we did not observe any direct effect of miR-17 on 
the TNF pathway. Indeed, miR-17 action did not involve TNF or 
NF-κB, as demonstrated by promoter-luciferase assays. More-
over, one of the identified targets, ASK1, was not affected by 
miR-17 transfection in either in vitro or in vivo experiments. In con-
trast to results obtained in mesenchymal stem cells (19), we did not 
observe down-regulation of the Smad pathway by miR-17 in RA FLS.
Transfection with miR-17 also protected the mice from bone 
erosions and cartilage damage. This protective effect was pre-
sumably the result of reduced inflammation and immune cell infil-
tration, reduction in osteoclasts, and expression of RANKL in the 
synovial tissue. This might be due to the silencing of STAT3, as it 
is suggested that STAT3 is directly responsible for RANKL expres-
sion (4,20,21). However, RANKL expression was not detectable 
in RA FLS, as previously shown (22). These findings possibly 
implicate other prominent cell sources of RANKL, such as lym-
phocytes and monocytes (23,24).
In RA, TNF and IL-6 are known to be prominent proin-
flammatory cytokines involved in its pathophysiology and 
expressed especially in the synovial tissue, along with IL-1 
and IL-17 (25). RA FLS are known to be an important source 
of IL-6 production within the inflamed synovium (26). Of note, 
when we stimulated RA FLS with TNF, we observed a sig-
nificant reduction not only in IL-6 secretion, but also in the 
other IL-6 family cytokine LIF, by miR-17. We compared the 
effect of miR-17 to that of the JAK1 inhibitor ruxolitinib (27) 
and observed a similar effect, suggesting a common mech-
anism of action. TNF is well known to induce expression of 
IL-6 through activation of NF-κB and MAPKs (28). However, 
recent studies suggest that IL-6 production and secretion 
also involve an autocrine feedback loop through other IL-6 
family members, especially LIF, LIFR, and different signaling 
partners such as JAK1, Tyk2, STAT3, and/or STAT4, driving 
a sustained activation and secretion of proinflammatory medi-
ators in RA FLS (3). RA FLS do not express IL-6R, although 
they express LIFR composed of gp130 and LIFR chains (3,4,29). 
We believe that miR-17, by directly targeting at least the 
JAK1/STAT3 axis, indirectly reduces LIF and IL-6 produc-
tion and acts as a negative regulator of this feedback loop 
(Figure 6C). In our experiments, miR-17 did not affect STAT4 
expression levels in either RA FLS or synovial tissue from mice 
with CIA. In mouse synovial tissue, Tyk2 was significantly 
reduced by miR-17, but this was not the case in RA FLS.
Interestingly, blocking the pathogenic effect of proinflammatory 
cytokines such as IL-6 (IL-6R blockade, JAK Inhibitors) (30,31) or 
TNF is the common strategy for RA therapy. In the present study, 
we confirmed that miR-17 expression was significantly decreased, 
especially in erosive RA phenotypes. By restoring miR-17 levels in 
the synovial tissue by local injection and transfection, we were able 
to significantly reduce inflammation and structural damage. These 
findings suggest that miR-17 acts as a regulator of synovial inflam-
mation. The disruption of miR-17 expression results in a loss of inhi-
bition of proinflammatory pathways, especially IL-6, and leads to an 
erosive phenotype in RA.
This study is the first to demonstrate an antiinflamma-
tory and structural role of miR-17 in vivo. Moreover, we have 
described in detail the mechanisms of action of miR-17 and have 
demonstrated an effect of miR-17 on the JAK/STAT pathway 
through direct targeting of JAK1 and STAT3. Very few studies 
have examined the expression of miRNA locally in RA synovium, 
and there are currently no data on synovial miRNA expression 
in relation to structural damage. This work allowed us to identify 
a miRNA significantly associated with an erosive phenotype in 
early and established RA, and further applications could include 
the study of miR-17 as a potential biomarker of erosive RA in a 
dedicated cohort. Moreover, miR-17 could be envisaged as a 
potential local or systemic therapy in erosive RA.
Figure 6. MicroRNA-17 lipoplex suppresses the JAK1/STAT3 
pathway in the ankles of mice with collagen-induced arthritis 
(CIA). A, On day 4, injection of miR-17 into the ankles of mice with 
CIA (n = 6 or n = 9) significantly reduced the expression of Jak1, 
Tyk2, and Stat3, but not Stat4, compared to control-injected mice 
(n = 7 or n = 9), as assessed by reverse transcription–quantitative 
polymerase chain reaction. B, On day 7, miR-17 significantly 
reduced synovial activation/phosphorylation of STAT3 as assessed 
by immunohistochemistry. Representative images (right) and 
quantification of the stained areas (left) are shown. Symbols represent 
individual ankles; bars show the mean ± SEM. * = P < 0.05; ** = 
P < 0.005, by Mann-Whitney U test. C, Model shows a proposed 
mode of action of miR-17 in arthritic joints. Overexpression of miR-
17 in synovial fibroblasts does not impact TNF signaling but targets 
an autocrine-amplifying loop involving IL-6 family members and ≥2 
signaling partners, JAK1 and STAT3. NA = nonarthritic, noninjected 
ankles (n = 2) (see Figure 4 for other definitions). Color figure can 
be viewed in the online issue, which is available at http://onlinelibrary.
wiley.com/doi/10.1002/art.41441/abstract.
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